We, therefore, hypothesize that PARPi treatment leads to increased PGF expression in tumors, which in turn facilitates pro-survival signaling in FLT1-proficient (but not FLT1-deficient) tumor cells and culminates in the development of PARPi resistance. This evidence concerns the gene PGF and neoplasm.